Investigational Mitochondrial Agent Shows Early Survival Signal in Glioblastoma

Preliminary data from an ongoing phase 2 trial (NCT04752813) suggest that adding the investigational mitochondrial agent BPM31510 to standard chemoradiation may extend overall survival in patients with newly diagnosed glioblastoma, including those with tumors historically associated with the poorest prognosis.¹

Among 39 evaluable patients enrolled in the multicenter, single-arm, open-label study, median overall survival was 19.3 months, nearly double published historical benchmarks for patients treated with standard therapy alone. The signal was most pronounced in patients with O6-methylguanine-DNA methyltransferase (MGMT) unmethylated tumors—a subgroup that typically derives limited benefit from temozolomide (Temodar) and radiotherapy. In the 24 unmethylated patients evaluated, median overall survival was 29.3 months, compared with a historical range of 12.7 to 15.5 months. Median overall survival in the MGMT-methylated cohort had not yet been reached at the time of the data cutoff because of ongoing survival among enrolled patients, BPGbio, the sponsor, reported.

The company cautioned that the findings are preliminary, unaudited, and still being collected; a fully audited topline readout is anticipated in fall 2026.

“As the data continue to mature, we are increasingly encouraged by the preliminary findings emerging from both cohorts, particularly the overall survival trends observed in the cohort with MGMT unmethylated glioblastoma,” said Niven R. Narain, PhD, president and CEO of BPGbio, in a news release. “These findings further reinforce our belief that targeting mitochondrial dysfunction and altered tumor metabolism may represent an important new therapeutic approach for aggressive solid tumors such as [glioblastoma]. We look forward to advancing the program toward topline and final data readout.”

Trial Design

The phase 2 study is evaluating BPM31510, a lipid nanodispersion formulation of oxidized coenzyme Q10 administered with vitamin K1, as a neoadjuvant and concurrent therapy alongside standard-of-care radiotherapy and temozolomide in patients with newly diagnosed glioblastoma who had not received prior treatment.² The single-arm, open-label study has completed enrollment, with 51 patients enrolled across multiple US cancer centers; primary end points are progression-free survival at 6 and 12 months, with overall survival and safety as secondary end points.

Safety

BPM31510 was reported to be generally well tolerated when combined with standard chemoradiation, with no new drug-related serious adverse events observed among treatment-naive patients in the frontline setting.¹ Detailed safety tabulations, including grade distribution and adverse event terms, were not included in the press release and have not yet been published in a peer-reviewed format.

Mechanism and Context

BPM31510 is designed to target dysregulated mitochondrial metabolism in tumor cells, aiming to shift cellular energy production from glycolysis toward oxidative phosphorylation and to restore apoptotic signaling that is often suppressed in glioblastoma. Glioblastoma remains the most common and aggressive primary malignant brain tumor in adults, and outcomes have changed little despite decades of investigation into multimodal treatment approaches. BPM31510 has received orphan drug designation from the FDA for glioblastoma and pancreatic cancer, among other indications.

REFERENCES

1. BPGbio Reports Encouraging Preliminary Data from Ongoing Phase 2 Study of BPM31510 in Newly Diagnosed Glioblastoma. News release. BPGbio. July 15, 2026. Accessed July 16, 2026. https://tinyurl.com/mryxdmfz

2. A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB). ClinicalTrials.gov. Updated January 26, 2026. Accessed July 16, 2026. https://clinicaltrials.gov/study/NCT04752813